Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Sangamo Therapeutics Inc’s stock clocked out at $0.48, down -4.11% from its previous closing price of $0.5. In other words, the price has decreased by -$4.11 from its previous closing price. On the day, 3.35 million shares were traded. SGMO stock price reached its highest trading level at $0.5032 during the session, while it also had its lowest trading level at $0.4761.
Ratios:
To gain a deeper understanding of SGMO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.88 and its Current Ratio is at 0.88. In the meantime, Its Debt-to-Equity ratio is 4.07 whereas as Long-Term Debt/Eq ratio is at 4.07.
On December 13, 2024, Truist Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $7.
H.C. Wainwright reiterated its Buy rating for the stock on December 10, 2024, and also maintained the target price at $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 162392240 and an Enterprise Value of 158200240. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.94 while its Price-to-Book (P/B) ratio in mrq is 24.89. Its current Enterprise Value per Revenue stands at 4.812 whereas that against EBITDA is -1.511.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.28, which has changed by -0.73821986 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $2.84, while it has fallen to a 52-week low of $0.38. The 50-Day Moving Average of the stock is -13.22%, while the 200-Day Moving Average is calculated to be -20.21%.
Shares Statistics:
It appears that SGMO traded 6.47M shares on average per day over the past three months and 7542530 shares per day over the past ten days. A total of 336.49M shares are outstanding, with a floating share count of 328.24M. Insiders hold about 2.45% of the company’s shares, while institutions hold 18.72% stake in the company. Shares short for SGMO as of 1764288000 were 17420411 with a Short Ratio of 2.69, compared to 1761868800 on 14190116. Therefore, it implies a Short% of Shares Outstanding of 17420411 and a Short% of Float of 5.2199997.
Earnings Estimates
Sangamo Therapeutics Inc (SGMO) is currently under the scrutiny of 2.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.4 and -$0.42 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.23, with 2.0 analysts recommending between -$0.12 and -$0.34.
Revenue Estimates
In. The current quarter, 4 analysts expect revenue to total $40.25M. It ranges from a high estimate of $100M to a low estimate of $10M. As of. The current estimate, Sangamo Therapeutics Inc’s year-ago sales were $7.55MFor the next quarter, 4 analysts are estimating revenue of $20.55M. There is a high estimate of $24.8M for the next quarter, whereas the lowest estimate is $16.3M.
A total of 4 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $125.3M, while the lowest revenue estimate was $35.3M, resulting in an average revenue estimate of $65.55M. In the same quarter a year ago, actual revenue was $57.8MBased on 4 analysts’ estimates, the company’s revenue will be $55.38M in the next fiscal year. The high estimate is $114.2M and the low estimate is $8.6M.
